Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ATOSSA THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for ATOSSA THERAPEUTICS, INC.

ATOS

ATOSSA THERAPEUTICS, INC.

About ATOSSA THERAPEUTICS, INC.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and related conditions. Its lead product candidate, oral (Z)-endoxifen, a selective estrogen receptor modulator, targets prevention and treatment of estrogen receptor-positive breast cancer. The company advances drug candidates through clinical trials, leveraging third-party manufacturing and research partnerships, and aims to address unmet medical needs in oncology with patented therapies for a global patient base.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ATOSSA THERAPEUTICS, INC.

1
1
ATOSSA THERAPEUTICS, INC. Atossa Therapeutics Reports $9.6 Million Net Loss in Q1 2026, Faces Funding Challenges

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
ATOSSA THERAPEUTICS, INC. Atossa Therapeutics Reports $34.8 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
ATOSSA THERAPEUTICS, INC. Atossa Therapeutics Reports $23.8 Million Net Loss and Increased R&D Expenses for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ATOSSA THERAPEUTICS, INC. Atossa Therapeutics Reports $15.1 Million Net Loss and Increased R&D Expenses for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ATOSSA THERAPEUTICS, INC. Atossa Therapeutics Reports $6.7 Million Net Loss in Q1 2025, Focuses on Breast Cancer Treatment

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ATOSSA THERAPEUTICS, INC. Atossa Therapeutics Reports $25.5 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ATOSSA THERAPEUTICS, INC. Atossa Therapeutics Reports Decrease in Cash and Cash Equivalents, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments